Ampio pharmaceuticals' study shows ampion inhibits a key inflammatory pathway in covid-19 and lupus nephritis

Englewood, colo., april 6, 2021 /prnewswire/ -- ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the results of a pre-clinical study demonstrating that ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in covid-19 and lupus nephritis.
AMPE Ratings Summary
AMPE Quant Ranking